Transforming women’s health

Revolutionizing Pelvic Organ Prolapse Care

Tissue Lifting & Tensioning (TLT) delivers a minimally invasive, 10-minute solution that restores anatomy without bulky implants or permanent mesh.

6.6M
U.S. women affected
88%
Left untreated
10 min
Procedure time

The Arcus TLT Solution

Tissue Lifting & Tensioning designed for outpatient success

The Arcus TLT device restores anatomical support through a minimally invasive approach that pairs clinical simplicity with strong procedural economics.

Performed in-office or ASC with local anesthesia and rapid recovery. Simple 3-step access, capture, and fixation workflow. Scalable economics with single-use device margins and high throughput.
Procedure Visualization

TLT device positioning with clinical illustration style.

Why Now?

The perfect storm of market need, regulatory opportunity, and clinical demand

Arcus Medical is positioned for rapid adoption as surgeons seek minimally invasive alternatives to transvaginal mesh.

Massive Unmet Need

6.6M U.S. women suffer from POP; 88% remain untreated due to lack of minimally invasive options.

FDA Created Vacuum

Removal of transvaginal mesh opened a gap for safer, office-based innovation.

Immediate Reimbursement

Existing CPT codes (57240/50/60) enable reimbursement from day one.

Office-Based Care

No modern office or ASC solution exists today. Arcus fills the gap.

The TLT 3-Step Process

Patented simplicity for rapid adoption and consistent outcomes

1

Access

Minimally invasive access to the treatment area through a precise, controlled approach.

2

Capture

Proprietary mechanism captures and positions prolapsed tissue with controlled tension.

3

Fixate

Secure fixation restores normal anatomy and provides durable support.

Anatomical Restoration

TLT restores normal pelvic anatomy without synthetic mesh

Before TLT

Medical diagram: prolapse with descending organs.

After TLT

Medical diagram: restored anatomy with proper organ positioning.

Massive Market Opportunity

Everyone serves the 12% — we serve the 88%

150M

Total addressable market

Women globally affected by pelvic organ prolapse.

6.6M

Serviceable addressable market

U.S. women seeking treatment options.

5.8M

Serviceable obtainable market

Untreated women — the primary 88% segment.

Investment Highlights

Raising $1.5M seed to complete trials, regulatory prep, and early commercialization

Large Unmet Need

Only a small fraction of POP patients undergo surgical repair. Millions actively seek minimally invasive alternatives.

Proprietary Device

Patented TLT technology with U.S. filings and global markets planned. Protected IP position.

Existing CPT Reimbursement

Procedure aligns with established CPT codes, enabling immediate payment pathways.

Clear Exit Path

Strategic acquisition targets across women’s health and medtech portfolios.

Partner with Arcus Medical

Join us in transforming women’s health

Schedule a conversation to review clinical progress, investment materials, or partnership opportunities.